Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ambitions with a glimmer of hope. | The FDA was set to decide on GSK's ...

The Trump administration is inching closer to banning fluoride tablets and drops often prescribed to kids who don’t have ...

Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by ...

Trump has a penchant for inventing numbers to oversell his economic policies. He previously claimed that he’d already struck ...

Government takes action against 694 firms for drug quality issues after inspecting 905 units, leading to regulatory ...

Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

The Environmental Working Group (EWG) has shed new light on sunscreen safety in the U.S. with a new and eye-opening report.

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing ...

Biosimilars could make healthcare more affordable—but here’s why activists are pushing for major revisions and greater ...

GLP-1 medications, on average, can cost individuals $1,000 per month if their employers do not provide insurance coverage, Andrea Grande, a principal at Brown & Brown, said ...

When the U.S. Food and Drug Administration (FDA) convened a public expert panel to review the use of selective serotonin ...